$CMTG

Claros Mortgage Trust, Inc. (CMTG): Results of Operations and Financial Condition

Claros Mortgage Trust, Inc. (CMTG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cmtg-ex99_1.htm EX-99.1 EX-99.1 Claros Mortgage Trust, Inc. Reports Second Quarter 2026 Results New York, NY, July 29, 2026 – Claros Mortgage Trust, Inc. (NYSE: CMTG) (the “Company” or “CMTG”) today reported its financial results for the quarter ended June 30, 2026. The

Original reporting
Published Jul 29, 2026, 8:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CMTG
Bearish
high confidence
Mentioned
$CMTG
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CMTGBearishMed
01

Why it matters

Q2 results highlight elevated credit costs via CECL reserves and realized/unrealized loss activity through REO and held-for-sale reclassifications, while management emphasizes progress resolving watchlist assets and deleveraging.

02

Market read

Large CECL provisioning and distributable losses are the dominant new datapoints, but the subsequent liquidity and watchlist resolution progress may temper the downside case.

03

What to watch

Book value is $8.58 per share and net debt/equity and total leverage ratios improved after resolutions and deleveraging; traders may over-weight GAAP loss versus improving balance-sheet metrics and near-term resolution cadence.

Relevance 7/10Novelty 7/10Timing: after-hours following Q2 2026 results release and ahead of the July 30, 2026 earnings call

Background

Claros Mortgage Trust is an externally managed mortgage REIT focused on senior and subordinate loans on transitional commercial real estate assets.

Company-level read

Ticker impact

$CMTGBearishHigh confidence
Context

Claros Mortgage Trust reported Q2 2026 GAAP net loss of $255.4M and Distributable Loss of $90.8M, plus $208.8M CECL provisions.

Expected impact

Likely negative-to-volatile reaction as large CECL reserves and losses dominate, partially offset by watchlist resolutions and liquidity increases.

Evidence & confidence

This is a primary earnings-style disclosure (8-K Item 2.02) with specific loss/provision figures, CECL reserve levels, REO activity, and subsequent liquidity updates that directly affect credit risk and distributable earnings expectations.

Market effects

Reinforces that transitional commercial mortgage REITs are still booking elevated CECL reserves, supporting a cautious read-through on sector credit quality.

No specific regional macro driver is disclosed beyond U.S. major markets exposure.

Limited, as the disclosure is company-specific and not tied to global funding or cross-border events.

Counterpoint

The watchlist held-for-investment loans declined sharply and subsequent events show multiple resolutions and a liquidity increase, which could reduce forward credit losses versus the quarter’s headline CECL expense.

Key entities

  • Claros Mortgage Trust, Inc.

    Reported Q2 2026 financial results, CECL reserve changes, REO/held-for-sale activity, liquidity, and subsequent loan resolutions.

  • Richard Mack

    CEO and Chairman, quoted on progress resolving watchlist assets and deleveraging.

Related articles

$LLYMedAI 8/10

Lilly Highlights Sleep Apnea Drug Progress and Sleep-Wake Disorder Acquisition in Q2 Report

Eli Lilly reported Q2 2026 results, saying worldwide revenue rose 48% to $23.0B, driven by volume growth led by Mounjaro and Zepbound, and raised full-year revenue guidance to $85B-$87B. In pipeline updates, the company said its triple agonist retatrutide improved obstructive sleep apnea in trials. Lilly also completed its acquisition of Centessa Pharmaceuticals to advance sleep-wake disorder treatments.

$QTIMedAI 8/10

QT Imaging (QTI) Q2 2026 Earnings Call Transcript

QT Imaging Holdings (QTI) reported Q2 2026 revenue of $7.4 million, up 103% year over year, driven by 15 scanner shipments. First-half revenue was $14 million. Fiscal 2026 guidance calls for about $39 million revenue. Q2 gross margin was 41%; operating loss $1.9 million and net loss $11.1 million. Company extended debt to 2029 and raised $10 million via an offering.

$FENCMed

Adherex Technologies Q2 Earnings Call Highlights

Fennec Pharmaceuticals (NASDAQ:FENC) reported Q2 results on an earnings call. Net product sales were $17.1 million, up 78% year over year. Non-GAAP adjusted EBITDA was $2.8 million versus a $1.2 million loss a year earlier. Cash and cash equivalents were $41.2 million at June 30, 2026. Management cited PEDMARK momentum and no quantitative 2026 revenue outlook.

$MIDDMedAI 8/10

Middleby Q2 Earnings Call Highlights

Middleby (NASDAQ:MIDD) said dealer-channel growth remains positive but should moderate in H2, with Q3 and Q4 growth driven mainly by chain customers. Q2 organic adjusted EBITDA margin was 25.8%, below expectations due to mix, inflation and ice and beverage investments. Q2 adjusted EBITDA was ~$193M and adjusted EPS $2.35. Full-year organic growth outlook raised to 6% to 8%.

$HROWMed

Harrow Q2 Earnings Call Highlights

Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.

$LIQTMedAI 9/10

LiqTech (LIQT) Q2 2026 Earnings Call Transcript

LiqTech International (LIQT) reported Q2 FY2026 revenue of $4.4 million, down 12% year over year, citing lower Water for Energy activity and production delays in diesel particulate filters. Gross margin was 8.4% and net loss widened to $3.1 million. Full-year revenue guidance was revised to $20-$23 million. The June offering raised about $18 million net proceeds.